Citations 2
Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis
Abreu, María T. , Siegmund, Britta , Surace, Lindsey, Erondu, Ngozi, Chen, Minhu, Chachu, Karen A., Matsuoka, Katsuyoshi , Limdi, Jimmy K. , Arthur, Edmund, Houck, Nicole, Marano, Colleen , Vetter, Marion L., Zou, Bin , Zhan, Joyce, Frustaci, Mary Ellen, Kannan, A K, Rydzewska, Grazyna, Loftus, Edward V. , Jairath, Vipul
New England Journal of Medicine | October 14, 2026 | Volume: 395 | Issue: 15 | Pages: 1495-1504
O60 Icotrokinra, a targeted oral peptide that blocks IL-23 receptor activation, in moderate-to-severe ulcerative colitis: week 12 results from ANTHEM-UC
Limdi, Jimmy, Abreu, M T, Siegmund, Britta, Surace, Lindsey, Erondu, Ngozi, Chen, Minhu, Chachu, Karen, Louis, Edouard, Matsuoka, Katsuyoshi, Houck, Nicole, Frustaci, Mary Ellen, Zou, Bin, Rydzewska, G, Loftus, Edward V, Jairath, Vipul, Siegmund, Britta, Erondu, Ngozi, Chachu, Karen A., Matsuoka, Katsuyoshi , Arthur, Edmund, Frustaci, Mary Ellen, Zou, Bin , Rydzewska-Wyszkowska, Grażyna , Loftus, Edward V , Jairath, Vipul
Oral Abstracts | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: A38-A39